JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series B financing rounds, raising a total of RMB 700 million (USD 102.5 million). Investors include SinoRock, Guanghua Wutong Equity Investment Fund, YuanHengLiZhen, Weigao Holding, and HM Capital. The funding follows a Series A round led by GL Ventures in December 2021.
Company Profile
JJET offers a comprehensive range of electrophysiological products, including a magnetic 3D system, electrophysiological multi-channel recorder, radio frequency ablation instrument, PFA ablation system, and related catheters. The company was the first in China to launch a magnetoelectric positioning 3D PFA solution.
Regulatory Progress
JJET’s LEAD-PFA pulsed electric field ablation system is in the follow-up stage of its regulatory clinical study and is expected to be the first of its kind approved in China. The system represents a significant advancement in cardiac electrophysiology treatment.-Fineline Info & Tech
